| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 08/15/2006 | US7090844 monoclonal antibody comprising a heavy chain amino acid; treatment of disorders associated with increased activity of MUC18, in particular, tumors, such as melanomas. |
| 08/15/2006 | US7090843 immunotherapy; fusion proteins; antitumor agents; for treatment and prevention of hodgkin's disease |
| 08/15/2006 | US7090842 antigen-binding fragment comprises immunoglobulin variable region light chains and heavy chains, produced by hybridoma; fusion proteins |
| 08/15/2006 | US7090835 Modified colony stimulating factor for treatment of hematopoietic disorder |
| 08/15/2006 | CA2258752C Naphthyridines which affect il-4 and g-csf |
| 08/15/2006 | CA2190983C New lipid esters of nucleoside monophosphates and their use as immunosuppressive drugs |
| 08/15/2006 | CA2155329C Acylfulvene analogues as antitumor agents |
| 08/15/2006 | CA2107439C Phospholipid derivatives containing phosphorous, arsenic, antimony or bismuth |
| 08/10/2006 | WO2006084281A1 Inhibitors of e1 activating enzymes |
| 08/10/2006 | WO2006084264A2 Cd20 antibody variants and uses thereof |
| 08/10/2006 | WO2006084210A2 Hif modulating compounds and methods of use thereof |
| 08/10/2006 | WO2006084017A2 Phenyl-substituted pyrimidine compounds useful as kinase inhibitors |
| 08/10/2006 | WO2006084016A1 ACID ADDITION SALTS OF Ac-PHSCN-NH2 |
| 08/10/2006 | WO2006084015A2 Raf inhibitor compounds and methods |
| 08/10/2006 | WO2006083936A2 Anti-ephb2 antibodies and methods using same |
| 08/10/2006 | WO2006083908A1 Crystalline 1h-imidazo[4,5-b]pyridin-5-amine,7-[5-[(cyclohexylmethylamino)-methyl]-1h-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses |
| 08/10/2006 | WO2006083005A1 Fused pyrimidine derivative and used thereof |
| 08/10/2006 | WO2006082952A1 Amide compound |
| 08/10/2006 | WO2006082428A2 Combination therapies using hdac inhibitors |
| 08/10/2006 | WO2006082404A1 Compounds having tie2 (tek) inhibitory activity |
| 08/10/2006 | WO2006082392A1 Pyrazolylaminopyridine derivatives useful as kinase inhibitors |
| 08/10/2006 | WO2006082373A1 Pyrimidine compounds having ties (tek) inhibitory activity |
| 08/10/2006 | WO2006082371A1 Pyrimidine compounds having tie2 (tek) inhibitory activity |
| 08/10/2006 | WO2006082309A1 1-h-pyrrole-2-carboxamides and imidazole-5-carboxamides and use thereof as fak, kdr and tie2 kinase modulators for the treatment of cancer |
| 08/10/2006 | WO2006082304A2 Novel peptides which interact with anti-apoptotic members of the family of bcl-2 proteins and use thereof |
| 08/10/2006 | WO2006082303A1 Motif of beclin protein which interacts with anti-apoptotic members of the family of bcl-2 proteins and use thereof |
| 08/10/2006 | WO2006082107A1 Thiazolidinones for use as inhibitors of polo-like kinase (plk) |
| 08/10/2006 | WO2006082098A1 Riproximin , a novel type ii ribosome-inactivating protein and uses thereof |
| 08/10/2006 | WO2006082071A1 Method for producing a drug extract that contains hydroxystilbene |
| 08/10/2006 | WO2006082068A1 Use of an active ingredient combination that contains hydroxystilbene for preventing and/or treating diseases |
| 08/10/2006 | WO2006082053A1 7-ethyl-10-hydroxy-camptothecin lipid ester derivatives |
| 08/10/2006 | WO2006081994A2 Isolation of n-butylbenzenesulfonamide, synthesis of benzenesulfonamide derivatives, and use of n-butylbenzenesulfonamide and benzenesulfonamide derivatives for the treatment of benign prostate hyperplasia and/or prostate carcinoma |
| 08/10/2006 | WO2006081985A1 Combined treatment with an n4-(substituted-oxycarbonyl)-5’-deoxy-5-fluorocytidine derivative and an epidermal growth factor receptor kinase inhibitor |
| 08/10/2006 | WO2006081963A1 Ibandronate polymorph a |
| 08/10/2006 | WO2006081962A1 Ibandronate polymorph b |
| 08/10/2006 | WO2006081740A1 The synergistically pharmaceutical composition of baicalein and baicalin for inhibiting tumor |
| 08/10/2006 | WO2006081722A1 A purification and cultivation method of ocean sponge pluripotent stem cell |
| 08/10/2006 | WO2006081631A1 Adjuvanting material |
| 08/10/2006 | WO2006081616A1 Classes of compounds that interact with integrins |
| 08/10/2006 | WO2006069208A3 Novel farnesyl protein transferase inhibitors as antitumor agents |
| 08/10/2006 | WO2006065828A3 Novel farnesyl protein transferase inhibitors and their use to treat cancer |
| 08/10/2006 | WO2006062982A3 Urea inhibitors of map kinases |
| 08/10/2006 | WO2006053778A3 Amide derivatives, their manufacture and use as pharmaceutical agents |
| 08/10/2006 | WO2006033795A3 Substituted pyrazolo [1, 5-a] pyrimidines for inhibiting abnormal cell growth |
| 08/10/2006 | WO2006027300A3 Carrier conjugates of gnrh-peptides |
| 08/10/2006 | WO2006024492A3 Medical implant provided with inhibitors of atp synthesis |
| 08/10/2006 | WO2006024490A3 Methods and compositions for the treatment of cell proliferation |
| 08/10/2006 | WO2006024489A3 Methods and compositions for the treatment of cell proliferation |
| 08/10/2006 | WO2006023714A3 Dithiocarbamate derivatives and their use for treating cancer |
| 08/10/2006 | WO2006021653A3 Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof |
| 08/10/2006 | WO2005120166A3 Antibodies for selective apoptosis of cells |
| 08/10/2006 | WO2005078124A3 Diagnostic marker for cancer |
| 08/10/2006 | WO2005041856A3 Use of 2-thia-dibenzo[e, h]azulenes for the treatment and prevention of central nervous system diseases and disorders |
| 08/10/2006 | WO2003065999A3 Proliferated cell lines and uses thereof |
| 08/10/2006 | US20060179496 Nucleic acid sequences differentially expressed in cancer tissue |
| 08/10/2006 | US20060179494 Non-human animal exhibiting bone metastasis of tumor cells |
| 08/10/2006 | US20060178409 Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors |
| 08/10/2006 | US20060178382 Chinazoline derivatives as aurora kinase inhibitors |
| 08/10/2006 | US20060178376 Novel process for the preparation of hexacyclic compounds |
| 08/10/2006 | US20060178371 7-amino-pyrrazolo[1,5-a]pyrimidine derivatives, useful in the treatment and prevention of proliferative diseases, for example, cancer, inflammation and arthritis |
| 08/10/2006 | US20060178365 Optionally oxidized 6-(2-(5-methylthio-2-pyrimidinyloxy)ethoxy)-2-phenylpyrimidin-4-yl-substituted sulfamides |
| 08/10/2006 | US20060178338 Use of 5-substituterd nucleosides for reinforcing the apoptotic effect of cytostatic drugs |
| 08/10/2006 | US20060178336 Oral administration of therapeutic agent coupled to transporting agent induces tolerance |
| 08/10/2006 | US20060178327 Inhibition of gene expression by delivery of specially selected double stranded or other forms of small interfering RNA precursors enabling the formation and function of small interfering RNA in vivo and in vitro |
| 08/10/2006 | US20060178318 Use of aurora kinase inhibitors for reducing the resistance of cancer cells |
| 08/10/2006 | US20060178300 Heterocarpine, a plant-derived protein with anti-cancer properties |
| 08/10/2006 | US20060178298 Aplidine and aplidine analogues are of use for the treatment of cancer, in particular in the treatment of leukemias and lymphomas, especially in combination therapies |
| 08/10/2006 | US20060178295 androgen steroid conjugated with one or more mammalian proteins; diagnosis or treatment of solid cancer and hematological malignancies; exhibit a synergistic action together with a cytoskeleton-acting drug such as Taxol (reg); prostate cancer |
| 08/10/2006 | US20060177906 IGF-I responsive gene and use thereof |
| 08/10/2006 | US20060177901 Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
| 08/10/2006 | US20060177877 Methods for identifying combinations of entities as therapeutics |
| 08/10/2006 | US20060177861 Novel compositions and methods in cancer associated with altered expression of MCM3AP |
| 08/10/2006 | US20060177819 genetic engineered polynucleotides comprising nucleotide sequences that code alphavirus replication recognition sequences, nonstructural proteins and heterologous polynucleotides; infectious, replication-defective alphavirus particles used for immunotherapy, treatment of cancer and gene delivery |
| 08/10/2006 | US20060177543 Process for producing liquid formulation containing raw yeast and liquid formulation |
| 08/10/2006 | US20060177528 Formulation Of A Mixture Of Free-B-Ring Flavonoids And Flavans As A Therapeutic Agent |
| 08/10/2006 | US20060177523 Administration of a thiol-based chemoprotectant compound |
| 08/10/2006 | US20060177517 Antiinflammtory agent and antiinflammatory medical material |
| 08/10/2006 | US20060177506 Release control compositions |
| 08/10/2006 | US20060177495 Polymer-lipid delivery vehicles |
| 08/10/2006 | US20060177457 Are designed to produce both Type 1 and Type 2 phototherapeutic effect at once using dual wavelength light source that will produce singlet oxygen and free radicals at the lesion of interest; for dual phototherapy of tumors and other lesions |
| 08/10/2006 | US20060177456 Apo-2 receptor antibodies |
| 08/10/2006 | US20060177449 Antibody and use thereof |
| 08/10/2006 | US20060177443 Integrin antagonists |
| 08/10/2006 | US20060177432 Methods and reagents for protease inhibition |
| 08/10/2006 | US20060177423 Composition and method for killing of tumours |
| 08/10/2006 | US20060177420 treatment of a tumor by administering to a patient an effective amount of active dendritic cells (DC) that are tumor-specific and secrete IL12 |
| 08/10/2006 | US20060177373 Low density radionuclide-containing particulate material |
| 08/10/2006 | DE102005005542A1 Preparing interleukin-2 (IL-2) for pharmaceutical use, by adding sodium dodecyl sulfate to composition comprising IL-2, removing precipitated covalently-linked IL-2 multimers, and reducing sodium dodecyl sulfate concentration |
| 08/10/2006 | DE102005005399A1 Use of 2,4-dihydroxy-3-methylbenzoate derivatives for preparing medicaments or as basic substance for the development of other agents used for treating benign prostate hyperplasia, prostate carcinoma or spinobulbar muscular atrophy |
| 08/10/2006 | DE102005005395A1 New thiazolidinone compounds are polo-like kinase inhibitors, useful for treating e.g. cancer, autoimmune diseases, cardiovascular diseases, infectious diseases, nephrological diseases and viral diseases |
| 08/10/2006 | DE102005005276A1 Use of a hydroxystilbene-containing active substance combination containing resveratrol and piceatannol precursors, to prevent and/or treat diseases caused by increased serum interleukin-6 level e.g. depression |
| 08/10/2006 | DE10141528B4 Platin(II)- und Platin(IV)-Komplexe und ihre Verwendung Platinum (II) - and platinum (IV) complexes and their use |
| 08/10/2006 | CA2597171A1 Antibodies to oncostatin m receptor |
| 08/10/2006 | CA2596973A1 Raf inhibitor compounds and methods |
| 08/10/2006 | CA2596967A1 Thiazolidinones for use as inhibitors of polo-like kinase (plk) |
| 08/10/2006 | CA2596759A1 Local treatment of neurofibromas |
| 08/10/2006 | CA2596754A1 Crystalline 1h-imidazo[4,5-b]pyridin-5-amine,7-[5-[(cyclohexylmethylamino)-methyl]-1h-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its uses for the treatment of inflammatory, autoimmune and proliferative diseases and disorders |
| 08/10/2006 | CA2596730A1 Adjuvanting material comprising pam2cys or pam3cys covalently linked to a metal chelating group |
| 08/10/2006 | CA2596674A1 Novel peptides which interact with anti-apoptotic members of the family of bcl-2 proteins and use thereof |
| 08/10/2006 | CA2596672A1 Motif of beclin protein which interacts with anti-apoptotic members of the family of bcl-2 proteins and use thereof |